TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20153481

Group type: EXPERIMENTAL
Intervention: Analogy-making task with perceptual and relational matches
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Analogy-making task measuring reaction times
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Analogy-making task performance
Number of subjects: 3
Study: 18610817

Group type: EXPERIMENTAL
Intervention: Culturally appropriate intervention for Native Hawaiian women and their families
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 18
Study: 16236875

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1503

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 1503
Study: 12209673

Group type: EXPERIMENTAL
Intervention: Pemetrexed/gemcitabine combination
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 42
Study: 10617249

Group type: COMPARATOR
Intervention: Continuous 1 mg E2
Number of subjects: 1253

Group type: COMPARATOR
Intervention: 1 mg E2/30 microg NGM
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: 1 mg E2/90 microg NGM
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: 1 mg E2/180 microg NGM
Number of subjects: 1253
Study: 7856897

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg.kg‐1 followed by 1 mg.kg‐1.h‐1)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (doses < 10 mg.kg‐1)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (all doses)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Initial hematocrit
Number of subjects: 148
Study: 2023868

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment (3.0 MHz, 1.0 W/cm2 for 5 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo control (massage with gels without ultrasound for 5 min)
Number of subjects: 10
Study: 31355692

Group type: EXPERIMENTAL
Intervention: Metacognitive strategy intervention designed to improve planning difficulties
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual occupational therapy (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metacognitive strategy intervention
Number of subjects: 60
Study: 28285536

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted complete mesocolic excision (LCME)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Open complete mesocolic excision (OCME)
Number of subjects: 78
Study: 25545380

Group type: EXPERIMENTAL
Intervention: ZOL (zoledronic acid) 5 mg annually for 9 years (Z9)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (Z6P3) after 6 years of ZOL treatment
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: ZOL (Z9)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (Z6P3)
Number of subjects: 190
Study: 23372475

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 725

Group type: COMPARATOR
Intervention: No active intervention (control)
Number of subjects: 725
Study: 21324838

Group type: EXPERIMENTAL
Intervention: Dyadic efficacy instrument
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Dyadic efficacy
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Smokers with partners willing to quit
Number of subjects: 634
Study: 20061311

Group type: EXPERIMENTAL
Intervention: Combined intervention (CC + PST)
Number of subjects: 252
Study: 17047101

Group type: EXPERIMENTAL
Intervention: ESWL alone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ESWL combined with endoscopy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study: 16270636

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (certoparin 3000 anti Xa IU) subcutaneously once-daily
Number of subjects: 23078

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU) subcutaneously three-times daily
Number of subjects: 23078

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (certoparin)
Number of subjects: 23078

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 23078
Study: 11991461

Group type: EXPERIMENTAL
Intervention: CDC/TMD diagnosis of ID type III
Number of subjects: 69
Study: 10220121

Group type: EXPERIMENTAL
Intervention: Reboxetine (8‐10 mg/day)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Fluoxetine (20‐40 mg/day)
Number of subjects: 168
Study: 7601298

Group type: EXPERIMENTAL
Intervention: Thymomodulin treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2215953

Group type: EXPERIMENTAL
Intervention: 15‐diopter plastic press‐on Fresnel prisms (n = 18)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 39
Study: 394268

Group type: EXPERIMENTAL
Intervention: lidamidine hydrochloride (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: lidamidine hydrochloride (18 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 31320504

Group type: EXPERIMENTAL
Intervention: Music medicine (noise-canceling headphone-delivered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (1-2 mg intravenous)
Number of subjects: 0
Study: 28615931

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 25238118

Group type: EXPERIMENTAL
Intervention: Prefeed abdominal circumference (AC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gastric residual volume (GRV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 23289819

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg for 10 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20678791

Group type: EXPERIMENTAL
Intervention: Low frequency (1 Hz) rTMS applied to the anterior portion of the homologue to Broca's area for 20 min per day for 10 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham control condition
Number of subjects: 12
Study: 17724591

Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft (ICBG) either alone or augmented with local bone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local bone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft (ICBG)
Number of subjects: 0
Study: 16766412

Group type: EXPERIMENTAL
Intervention: 24-hour nicotine patch
Number of subjects: 20

Group type: COMPARATOR
Intervention: 16-hour nicotine patch
Number of subjects: 20
Study: 15534490

Group type: EXPERIMENTAL
Intervention: Subcutaneous CPG 7909 injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous CPG 7909 injection (second dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous CPG 7909 injection
Number of subjects: 0
Study: 11251475

Group type: EXPERIMENTAL
Intervention: Bicarbonate solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactate solution
Number of subjects: 20
Study: 9250117

Group type: EXPERIMENTAL
Intervention: Nutrient-fortified prepared meal plan
Number of subjects: 560

Group type: COMPARATOR
Intervention: Self-selected, mixed-food plan
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Both groups (compliant participants)
Number of subjects: 560
Study: 8296180

Group type: EXPERIMENTAL
Intervention: Regular deep relaxation training (15 min sessions, daily for 6 months)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Reference group (no relaxation training)
Number of subjects: 98
Study: 17165349

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg/kg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fentanyl 15 microg/kg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg/kg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 29551350

Group type: EXPERIMENTAL
Intervention: Eberconazole 1% otic solution
Number of subjects: 190

Group type: COMPARATOR
Intervention: Clotrimazole 1% solution
Number of subjects: 190
Study: 26560350

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 25721322

Group type: EXPERIMENTAL
Intervention: Project EX program
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 1546
Study: 22948946

Group type: EXPERIMENTAL
Intervention: Regular group dietary counselling and menu changes
Number of subjects: 429

Group type: COMPARATOR
Intervention: Advice on hostel menu only (Control)
Number of subjects: 429
Study: 20454958

Group type: EXPERIMENTAL
Intervention: Highly predictable stimulus location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpredictable stimulus location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very short saccadic latencies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased saccadic latencies (every 100 ms increase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulating duration of the stimulus
Number of subjects: 0
Study: 18793575

Group type: EXPERIMENTAL
Intervention: Avosentan 50 mg after a high-fat, high-calorie breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Avosentan 50 mg administered in the fasted state
Number of subjects: 12
Study: 15833397

Group type: EXPERIMENTAL
Intervention: Whitening/stain removing dentifrice (Regimen B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Whitening/stain removing dentifrice, tooth polish, tooth polisher and whitening/stain removing mouthwash (Regimen C)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard dentifrice (Regimen A)
Number of subjects: 63
Study: 11865128

Group type: EXPERIMENTAL
Intervention: CLON
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MPH
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CLON + MPH
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CLON alone
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MPH alone
Number of subjects: 136
Study: 10440146

Group type: EXPERIMENTAL
Intervention: Transatrial configuration (shocks delivered between the atrial coil and active can)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Triad configuration (shocks delivered between the right ventricular coil and an active can in common with the proximal atrial coil)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Triad configuration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Left atrial size as a clinical predictor
Number of subjects: 32
Study: 8847714

Group type: EXPERIMENTAL
Intervention: Preparatory interventions offering different levels of relaxation, control, and self‐efficacy
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Different types of preparatory interventions
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Interventions providing more coping elements
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Coping style interaction with intervention
Number of subjects: 231
Study: 2352762

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) with placebo (saline)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) with naloxone (50 mg)
Number of subjects: 11
Study: 103114

Group type: EXPERIMENTAL
Intervention: Combination of haloperidol and low dose piribedil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Piribedil alone
Number of subjects: 15
Study: 28392165

Group type: EXPERIMENTAL
Intervention: sorafenib or sunitinib (targeted therapy)
Number of subjects: 47
Study: 26835562

Group type: EXPERIMENTAL
Intervention: Standard Care with Vaccaria segetalis taped to the auricular location specific to lung function in TCM
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard Care with Vaccaria segetalis taped to random auricular locations (placebo)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 11
Study: 24717399

Group type: EXPERIMENTAL
Intervention: Zinc supplementation from 16 weeks until delivery
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Zinc plus multivitamins
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 675
Study: 21810400

Group type: EXPERIMENTAL
Intervention: New cytogenetics classification scheme for patients undergoing HCT
Number of subjects: 821

Group type: COMPARATOR
Intervention: Existing cytogenetics classifications
Number of subjects: 821
Study: 19541299

Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment for 2 months before surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Direct surgery without preoperative medical treatment
Number of subjects: 39
Study: 18347776

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15950139

Group type: EXPERIMENTAL
Intervention: COPD patients with previous diagnosis
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: COPD patients with worse lung function and HRQL
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: COPD patients with chronic symptoms
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: COPD in never smokers
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Wheezing as a symptom
Number of subjects: 363
Study: 12190134

Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac + 15 mg codeine phosphate
Number of subjects: 67

Group type: COMPARATOR
Intervention: Codeine alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac + codeine
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Codeine in combination
Number of subjects: 67
Study: 10655291

Group type: EXPERIMENTAL
Intervention: Follitropin alpha (Gonal-F)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Follitropin beta (Puregon)
Number of subjects: 296
Study: 8882400

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (0.8 mg of folic acid daily)
Number of subjects: 4862

Group type: COMPARATOR
Intervention: Trace element supplement (placebo-like)
Number of subjects: 4862
Study: 1519784

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 50 micrograms.h‐1
Number of subjects: 95

Group type: COMPARATOR
Intervention: Transdermal fentanyl 25 micrograms.h‐1
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 6831829

Group type: EXPERIMENTAL
Intervention: Combination of 500 mg acetaminophen and 65 mg caffeine
Number of subjects: 1518

Group type: COMPARATOR
Intervention: 500 mg acetaminophen alone
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study: 31418532

Group type: EXPERIMENTAL
Intervention: Brochure about venous disease and compression therapy (case group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: No brochure (control group)
Number of subjects: 136
Study: 28848056

Group type: EXPERIMENTAL
Intervention: Hands-on education
Number of subjects: 39

Group type: COMPARATOR
Intervention: Online education
Number of subjects: 39
Study: 27282543

Group type: EXPERIMENTAL
Intervention: Healthy norm condition
Number of subjects: 204

Group type: COMPARATOR
Intervention: Unhealthy norm condition
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Healthiness norm
Number of subjects: 204
Study: 24749634

Group type: EXPERIMENTAL
Intervention: Experiential avoidance during self-disclosure conversation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Experiential avoidance during small-talk conversation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Momentary experiential avoidance in everyday life
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sensitivity to situational threat
Number of subjects: 75
Study: 22502624

Group type: EXPERIMENTAL
Intervention: 1.0% copaiba essential oil preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20527063

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 18585701

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (therapeutic lifestyle modification)
Number of subjects: 120
Study: 16059597

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12377643

Group type: EXPERIMENTAL
Intervention: irinotecan + leucovorin (LV)/5‐fluorouracil (5‐FU)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: oxaliplatin + LV/5‐FU
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: irinotecan + oxaliplatin
Number of subjects: 101
Study: 10348287

Group type: EXPERIMENTAL
Intervention: Intensive doxorubicin-containing chemotherapy and whole-lung irradiation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Less aggressive treatment with 2 or 3 drugs without whole-lung irradiation
Number of subjects: 90
Study: 7586616

Group type: EXPERIMENTAL
Intervention: Naloxone 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ovine corticotrophin‐releasing hormone (oCRH) 1 microgram/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin 0.15U/kg
Number of subjects: 12
Study: 1849413

Group type: EXPERIMENTAL
Intervention: AVE‐5 regimen (etoposide 60 mg/m2 IV on day 1 and 120 mg/m2 orally on days 2-5)
Number of subjects: 78

Group type: COMPARATOR
Intervention: AVE‐1 regimen (etoposide 300 mg/m2 IV on day 1)
Number of subjects: 78
Study: 6418074

Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (TAM+) with Mitomycin-C plus Tegafur and Tamoxifen 20 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy alone (TAM-)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (TAM+) in curatively resected cases
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy alone (TAM-) in curatively resected cases
Number of subjects: 40
Study: 30693573

Group type: EXPERIMENTAL
Intervention: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 6 weeks
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 8 weeks
Number of subjects: 365

Group type: COMPARATOR
Intervention: Historical control (not specified in detail)
Number of subjects: 365
Study: 29138049

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) program consisting of motor control, stretching, and aerobic exercises
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pain neurophysiology education (PNE) plus therapeutic exercise (TE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Therapeutic exercise (TE) alone
Number of subjects: 56
Study: 27267785

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone rapidly dissolving tablets
Number of subjects: 313

Group type: COMPARATOR
Intervention: Generic buprenorphine
Number of subjects: 313
Study: 25144188

Group type: COMPARATOR
Intervention: Event-related potentials (ERPs) in LD NOS children during a semantic judgment priming task.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group during a semantic judgment priming task.
Number of subjects: 41
Study: 18925521

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 0
Study: 15083484

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 11236267

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 40
Study: 9296936

Group type: EXPERIMENTAL
Intervention: Pregnant women with hypertension
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 62
Study: 8253920

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (HCG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular progesterone
Number of subjects: 60
Study: 3122276

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31336393

Group type: EXPERIMENTAL
Intervention: Î±‐tocopherol acetate (150mg/L)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Pinus ponderosa leaves (150mg/L)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Combination of Pinus ponderosa leaves (70mg) and Î±‐tocopherol acetate (70mg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (IC)
Number of subjects: 360
Study: 27986684

Group type: EXPERIMENTAL
Intervention: RG-TFV rectal gel daily
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: RG-TFV rectal gel before and after receptive anal intercourse (RAI)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Daily gel regimen
Number of subjects: 195
Study: 27078991

Group type: EXPERIMENTAL
Intervention: Floating needle therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 24835833

Group type: EXPERIMENTAL
Intervention: UMEC 125 μg plus VI 25 μg
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: UMEC 62.5 μg plus VI 25 μg
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 2332

Group type: COMPARATOR
Intervention: UMEC plus VI
Number of subjects: 2332

Group type: COMPARATOR
Intervention: TIO
Number of subjects: 2332
Study: 22654431

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg twice daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ranitidine (300 mg twice daily)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 83
Study: 19626811

Group type: EXPERIMENTAL
Intervention: Intrathecal 1.25 mg hyperbaric bupivacaine plus cerebrospinal fluid 0.75 ml
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol 1‐1.5 mg/kg IV bolus dose and 6‐10 mg/kg/hr infusion
Number of subjects: 70
Study: 17366527

Group type: EXPERIMENTAL
Intervention: Once-daily ceftriaxone plus amikacin (C + A)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Imipenem monotherapy (control)
Number of subjects: 129
Study: 15270930

Group type: EXPERIMENTAL
Intervention: Community-based intervention including a mass media campaign and information to women visiting family planning clinics.
Number of subjects: 800

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided).
Number of subjects: 800